Comparison of Clinical Outcomes Between Second Generation Zotarolimus- vs Everolimus-Eluting Stents: Up to 10-Year Follow-Up

초록

Background There are limited long-term clinical outcome data comparing second-generation drug-eluting stents (DES), zotarolimus-eluting stent and everolimus-eluting stent. We sought to compare the efficacy and safety of zotarolimus- and everolimus--eluting stent in patients who underwent percutaneous coronary intervention (PCI) during 10-year clinical follow-up periods. Methods A total 1,509 consecutive patients who received PCI with zotarolimus-eluting (n = 690) or everolimus-eluting (n = 819) stents were enrolled. After propensity score matching (PSM), 2 PSM groups (496 pairs) were generated. The study endpoints were individual and composite clinical outcomes up to 10 years. Results During the 10-year follow-up period, the cumulative incidence of total death, cardiac death, myocardial infarction (MI), revascularization, target lesion revascularization (TLR), target vessel revascularization (TVR), non–target vessel revascularization (NTVR), stroke, major adverse cardiac events (MACE), TLR MACE, and major adverse cardiac and cerebrovascular events (MACCE) were similar between the 2 groups (Figure 1). Conclusions In our single-center, all-comer registry, second-generation DES comparison between zotarolimus-eluting stent and everolimus-eluting stent showed similar clinical outcomes up to 10-year follow-up periods.